8-KOther EventsExhibits & Filings

ALNYLAM PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Dec 13, 2006)

Filed December 13, 2006For Securities:ALNY

Summary

Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on December 13, 2006, to report on the execution of an underwriting agreement for a significant public offering of its common stock. The company entered into this agreement on December 12, 2006, with Banc of America Securities LLC as the underwriter. This filing indicates Alnylam is raising capital by selling 4,700,000 shares of its common stock. The shares are being sold at an initial public offering price of $22.00 per share, with the underwriter purchasing them from Alnylam at $21.57 per share. The shares were registered under a Form S-3 registration statement filed in November 2006, confirming regulatory compliance for this offering. This capital raise is a key event for investors, suggesting potential funding for ongoing research, development, and corporate expansion.

Key Highlights

  • 1Alnylam Pharmaceuticals entered into an underwriting agreement on December 12, 2006.
  • 2The agreement is for the issuance and sale of 4,700,000 shares of common stock.
  • 3The initial public offering price for the shares is set at $22.00 per share.
  • 4The underwriter, Banc of America Securities LLC, will purchase shares from Alnylam at $21.57 per share.
  • 5The offering was registered under a Form S-3 registration statement filed on November 9, 2006.
  • 6The filing includes the Underwriting Agreement (Exhibit 1.1) and a press release (Exhibit 99.1) announcing the pricing.

Frequently Asked Questions

The primary purpose of this 8-K filing is to report on Alnylam Pharmaceuticals' entry into an underwriting agreement for a public offering of its common stock and to provide details on the number of shares, the offering price, and the underwriter involved.

Alnylam is selling 4,700,000 shares of its common stock at an initial public offering price of $22.00 per share. The underwriter will purchase these shares from Alnylam at $21.57 per share.

The Form S-3 filing indicates that Alnylam had a previously effective registration statement with the SEC, allowing for a streamlined process to register the shares being offered in this public offering. It confirms regulatory readiness for the stock sale.

The underwriting agreement outlines the terms and conditions under which Banc of America Securities LLC, as the underwriter, will purchase the 4,700,000 shares from Alnylam and subsequently sell them to the public. It specifies the purchase price from the company and the intended public offering price.